U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Globenewswire -
Nổi bật :
MỚI NHẤT
QUAN TÂM
